Please enable JavaScript to continue using this application.

Compare $RNTX vs $SPRO | Chartloom

Compare

$RNTX vs $SPRO

Rein Therapeutics Inc · Spero Therapeutics Inc

RNTX

Rein Therapeutics Inc

SPRO

Spero Therapeutics Inc

Compare $RNTX vs $SPRO

Comparing Rein Therapeutics Inc and Spero Therapeutics Inc

RNTXRein Therapeutics Inc

SPROSpero Therapeutics Inc

RNTXRein Therapeutics Inc

Market cap

$68M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-36.5%

52W performance

-42.9%

FCF yield

-27.7%

SPROSpero Therapeutics Inc

Market cap

$69M

P/E (TTM)

9.42x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-3.3%

YTD performance

-48.9%

52W performance

-47.4%

FCF yield

28.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RNTX

SPRO

Detailed metrics comparison

RNTX

Rein Therapeutics Inc

SPRO

Spero Therapeutics Inc

Market Cap

RNTX$68M

SPRO$69M

Enterprise Value

RNTX$59M

SPRO$19M

Price

RNTX$0.79

SPRO$1.20

P/E Ratio

RNTXN/A

SPRO9.42x

P/S Ratio

RNTX0.00x

SPRO1.48x

EV/Sales

RNTX0.00x

SPRO0.40x

EV/EBITDA

RNTX0.00x

SPRO0.78x

P/B Ratio

RNTX1.25x

SPRO1.57x

P/FCF Ratio

RNTXN/A

SPRO3.55x

EV/FCF

RNTX-3.15x

SPRO0.96x

PEG Ratio

RNTXN/A

SPRON/A

Forward P/E (NTM)

RNTXN/A

SPRON/A

Forward P/S (NTM)

RNTXN/A

SPRON/A

Revenue (TTM)

RNTX$0

SPRO$47M

Revenue Growth (YoY)

RNTXN/A

SPRO-3.3%

Forward Rev Growth

RNTX113.7%

SPRO300.0%

Gross Margin (TTM)

RNTX0.0%

SPRO0.0%

Operating Margin (TTM)

RNTX0.0%

SPRO22.1%

EBITDA Margin (TTM)

RNTX0.0%

SPRO51.2%

Net Margin (TTM)

RNTX0.0%

SPRO15.7%

FCF Margin (TTM)

RNTXN/A

SPRO41.7%

Net Income (TTM)

RNTX$-50M

SPRO$7M

FCF (TTM)

RNTX$-19M

SPRO$20M

EPS (TTM)

RNTX-$0.74

SPRO$0.13

ROE (TTM)

RNTX-15323.0%

SPRO16.2%

ROA (TTM)

RNTX-11700.0%

SPRO12.6%

ROIC (TTM)

RNTX-14763.0%

SPRO16.2%

Cash

RNTX$9M

SPRO$51M

Debt

RNTX$0

SPRO$0

Net Cash/Debt

RNTX$9M

SPRO$51M

Current Ratio (TTM)

RNTX4.27x

SPRO6.12x

Quick Ratio (TTM)

RNTX4.26x

SPRO6.03x

Debt/Equity (TTM)

RNTX0.00x

SPRO0.00x

Debt/Assets (TTM)

RNTX0.0%

SPRO0.0%

Interest Coverage (TTM)

RNTXN/A

SPRON/A

Net Debt/EBITDA (TTM)

RNTX0.00x

SPRO0.00x

Beta

RNTX1.40

SPRO1.54

52W Performance

RNTX-42.9%

SPRO-47.4%

YTD Performance

RNTX-36.5%

SPRO-48.9%

% from 52W High

RNTX-63.6%

SPRO-61.0%

% from 52W Low

RNTX14.4%

SPRO11.1%

Asset Turnover (TTM)

RNTX0.00x

SPRO1.00x

FCF Yield (TTM)

RNTX-27.7%

SPRO28.2%

Earnings Yield (TTM)

RNTX-73.3%

SPRO10.6%

Dividend Yield (TTM)

RNTXN/A

SPRON/A

Rule of 40

RNTX0.0

SPRO38.4

EV/GP/RG

RNTXN/A

SPRON/A

Ticker research

View RNTX research View SPRO research

Metric	RNTX Rein Therapeutics Inc	SPRO Spero Therapeutics Inc
Market & Valuation
Market Cap	$68M	$69M
Enterprise Value	$59M	$19M
Price	$0.79	$1.20
P/E Ratio	N/A	9.42x
P/S Ratio	0.00x	1.48x
EV/Sales	0.00x	0.40x
EV/EBITDA	0.00x	0.78x
P/B Ratio	1.25x	1.57x
P/FCF Ratio	N/A	3.55x
EV/FCF	-3.15x	0.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$47M
Revenue Growth (YoY)	N/A	-3.3%
Forward Rev Growth	113.7%	300.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	22.1%
EBITDA Margin (TTM)	0.0%	51.2%
Net Margin (TTM)	0.0%	15.7%
FCF Margin (TTM)	N/A	41.7%
Net Income (TTM)	$-50M	$7M
FCF (TTM)	$-19M	$20M
EPS (TTM)	-$0.74	$0.13
ROE (TTM)	-15323.0%	16.2%
ROA (TTM)	-11700.0%	12.6%
ROIC (TTM)	-14763.0%	16.2%
Financial Health
Cash	$9M	$51M
Debt	$0	$0
Net Cash/Debt	$9M	$51M
Current Ratio (TTM)	4.27x	6.12x
Quick Ratio (TTM)	4.26x	6.03x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.40	1.54
52W Performance	-42.9%	-47.4%
YTD Performance	-36.5%	-48.9%
% from 52W High	-63.6%	-61.0%
% from 52W Low	14.4%	11.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.00x
FCF Yield (TTM)	-27.7%	28.2%
Earnings Yield (TTM)	-73.3%	10.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	38.4
EV/GP/RG	N/A	N/A
Ticker research	View RNTX research	View SPRO research

Valuation

P/E Ratio

SPRO

9.42x

P/S Ratio

RNTX

0.00x

SPRO

1.48x

EV/FCF

RNTX

-3.15x

SPRO

0.96x

Growth & revenue

Revenue Growth TTM

SPRO

-3.3%

Forward Revenue Growth

SPRO

300.0%

RNTX

113.7%

Profitability & performance

Gross Margin

RNTX

0.0%

SPRO

0.0%

ROE

SPRO

16.2%

RNTX

-15323.0%

FCF Yield %

SPRO

28.2%

RNTX

-27.7%

52-Week Performance

RNTX

-42.9%

SPRO

-47.4%

Detailed metrics comparison

RNTX

Rein Therapeutics Inc

SPRO

Spero Therapeutics Inc

Market Cap

RNTX$68M

SPRO$69M

Enterprise Value

RNTX$59M

SPRO$19M

Price

RNTX$0.79

SPRO$1.20

P/E Ratio

RNTXN/A

SPRO9.42x

P/S Ratio

RNTX0.00x

SPRO1.48x

EV/Sales

RNTX0.00x

SPRO0.40x

EV/EBITDA

RNTX0.00x

SPRO0.78x

P/B Ratio

RNTX1.25x

SPRO1.57x

P/FCF Ratio

RNTXN/A

SPRO3.55x

EV/FCF

RNTX-3.15x

SPRO0.96x

PEG Ratio

RNTXN/A

SPRON/A

Forward P/E (NTM)

RNTXN/A

SPRON/A

Forward P/S (NTM)

RNTXN/A

SPRON/A

Revenue (TTM)

RNTX$0

SPRO$47M

Revenue Growth (YoY)

RNTXN/A

SPRO-3.3%

Forward Rev Growth

RNTX113.7%

SPRO300.0%

Gross Margin (TTM)

RNTX0.0%

SPRO0.0%

Operating Margin (TTM)

RNTX0.0%

SPRO22.1%

EBITDA Margin (TTM)

RNTX0.0%

SPRO51.2%

Net Margin (TTM)

RNTX0.0%

SPRO15.7%

FCF Margin (TTM)

RNTXN/A

SPRO41.7%

Net Income (TTM)

RNTX$-50M

SPRO$7M

FCF (TTM)

RNTX$-19M

SPRO$20M

EPS (TTM)

RNTX-$0.74

SPRO$0.13

ROE (TTM)

RNTX-15323.0%

SPRO16.2%

ROA (TTM)

RNTX-11700.0%

SPRO12.6%

ROIC (TTM)

RNTX-14763.0%

SPRO16.2%

Cash

RNTX$9M

SPRO$51M

Debt

RNTX$0

SPRO$0

Net Cash/Debt

RNTX$9M

SPRO$51M

Current Ratio (TTM)

RNTX4.27x

SPRO6.12x

Quick Ratio (TTM)

RNTX4.26x

SPRO6.03x

Debt/Equity (TTM)

RNTX0.00x

SPRO0.00x

Debt/Assets (TTM)

RNTX0.0%

SPRO0.0%

Interest Coverage (TTM)

RNTXN/A

SPRON/A

Net Debt/EBITDA (TTM)

RNTX0.00x

SPRO0.00x

Beta

RNTX1.40

SPRO1.54

52W Performance

RNTX-42.9%

SPRO-47.4%

YTD Performance

RNTX-36.5%

SPRO-48.9%

% from 52W High

RNTX-63.6%

SPRO-61.0%

% from 52W Low

RNTX14.4%

SPRO11.1%

Asset Turnover (TTM)

RNTX0.00x

SPRO1.00x

FCF Yield (TTM)

RNTX-27.7%

SPRO28.2%

Earnings Yield (TTM)

RNTX-73.3%

SPRO10.6%

Dividend Yield (TTM)

RNTXN/A

SPRON/A

Rule of 40

RNTX0.0

SPRO38.4

EV/GP/RG

RNTXN/A

SPRON/A

Ticker research

View RNTX research View SPRO research

Metric	RNTX Rein Therapeutics Inc	SPRO Spero Therapeutics Inc
Market & Valuation
Market Cap	$68M	$69M
Enterprise Value	$59M	$19M
Price	$0.79	$1.20
P/E Ratio	N/A	9.42x
P/S Ratio	0.00x	1.48x
EV/Sales	0.00x	0.40x
EV/EBITDA	0.00x	0.78x
P/B Ratio	1.25x	1.57x
P/FCF Ratio	N/A	3.55x
EV/FCF	-3.15x	0.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$47M
Revenue Growth (YoY)	N/A	-3.3%
Forward Rev Growth	113.7%	300.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	22.1%
EBITDA Margin (TTM)	0.0%	51.2%
Net Margin (TTM)	0.0%	15.7%
FCF Margin (TTM)	N/A	41.7%
Net Income (TTM)	$-50M	$7M
FCF (TTM)	$-19M	$20M
EPS (TTM)	-$0.74	$0.13
ROE (TTM)	-15323.0%	16.2%
ROA (TTM)	-11700.0%	12.6%
ROIC (TTM)	-14763.0%	16.2%
Financial Health
Cash	$9M	$51M
Debt	$0	$0
Net Cash/Debt	$9M	$51M
Current Ratio (TTM)	4.27x	6.12x
Quick Ratio (TTM)	4.26x	6.03x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.40	1.54
52W Performance	-42.9%	-47.4%
YTD Performance	-36.5%	-48.9%
% from 52W High	-63.6%	-61.0%
% from 52W Low	14.4%	11.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.00x
FCF Yield (TTM)	-27.7%	28.2%
Earnings Yield (TTM)	-73.3%	10.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	38.4
EV/GP/RG	N/A	N/A
Ticker research	View RNTX research	View SPRO research